The U.S. Food and Drug Administration (FDA) granted a supplemental approval for atezolizumab (Tecentriq) on June 19, 2018. This approval, categorized as an efficacy supplement, indicates an expansion of the drug's approved therapeutic application, allowing for its use in additional patient populations or for new indications.
Background
Atezolizumab, marketed as Tecentriq, is an immunotherapy drug developed by Genentech Inc. It is part of a class of medications known as PD-L1 inhibitors, which work by blocking the PD-L1 protein found on tumor cells and tumor-infiltrating immune cells. By blocking PD-L1, atezolizumab helps to restore the immune system's ability to detect and fight cancer cells. Prior to this supplemental approval, atezolizumab had already received initial FDA approvals for various cancer indications, establishing its role in oncology. Supplemental applications are typically submitted to the FDA to request approval for changes to an already approved drug product, such as a new indication, a new dosage, or a new manufacturing process. In this case, the supplemental application specifically pertained to the drug's efficacy, suggesting new clinical data supported an expanded use.
What this means
This supplemental efficacy approval for atezolizumab signifies that the FDA has reviewed new clinical data and determined that the drug is effective for an expanded use, which could include a new patient population, a new type of cancer, or a different stage of an already approved cancer. For clinicians, this means a broader range of patients may now be eligible for treatment with atezolizumab, potentially offering a new therapeutic option where previous treatments may have been limited or ineffective. Researchers will likely find this approval relevant as it validates further clinical investigation into the drug's mechanisms and applications. Patient advocates will see this as an expansion of treatment access, potentially benefiting more individuals battling cancer. The approval reinforces atezolizumab's established profile as an important agent in cancer therapy.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for BLA 761034 S-10, categorized as an efficacy supplement for Tecentriq (atezolizumab), was granted on June 19, 2018, and is publicly accessible on accessdata.fda.gov.